Approval criteria for 5-ASA agents
Customize your policy alerts
Sign up for allcareadvantage Policy UMCCOMED062.2 alerts
Get alerted when Policy UMCCOMED062.2 changes without checking for updates manually.
Monitor payer policy activity
Defines prior authorization, coverage, quantity limits, and renewal criteria for 5-aminosalicylic acid (5-ASA) agents for treatment and maintenance of ulcerative colitis or Crohn's disease for AllCare Advantage members.
No material clinical or coverage changes in this revision.
Coverage and Medical Necessity Criteria
Initial Therapy and Coverage Logic
Covered when the following decision-path criteria are met:
If prescriber is not a gastroenterologist, deny prior authorization.
If not oral mesalamine, follow other branches or deny prior authorization.
Required per step therapy before coverage of mesalamine.
If yes, approve up to 8 weeks with quantity limit.
If yes, approve up to 1 year with quantity limit.
Approve only if documented inability to maintain remission at 2.4 g/day.
Adequate trial defined as >1 month at maximal dose without reduction or remission of symptoms.
Covered only for patients intolerant of sulfasalazine with prior trial of formulary generic mesalamine (Lialda) and one nonformulary mesalamine agent.
Formulary rectal suppositories approved for up to 8 weeks or until remission; non-formulary suppositories/enemas may be covered after trial of at least one formulary product.
Renewal Criteria
Renewal covered when the following are met:
If initial criteria were not met or efficacy is not documented, review under initial criteria or deny.
Requests are covered only when the stepwise criteria in the policy decision tree are met. At a minimum the request must document a funded diagnosis of ulcerative colitis or ulcerative proctitis and the medication must be prescribed by or in consultation with a gastroenterologist. If the prescriber is not a gastroenterologist and no consultation is documented, the prior authorization must be denied.
Requests lacking documentation of required prior trials — for example, absence of a trial of sulfasalazine or balsalazide where step therapy requires them — are excluded from coverage under these criteria. Non‑ulcerative indications (cases not documenting ulcerative colitis or ulcerative proctitis) are also excluded.
Formulary preferences and sequencing apply: coverage favors the preferred generic mesalamine formulation (mesalamine 1.2 g, generic Lialda®) with approval limited to protocolized durations (induction and maintenance) and quantity limits. Non‑formulary oral or rectal products require documented prior trials of the preferred formulary product(s) before coverage will be considered.
Use of oral 5‑ASA agents for induction in Crohn's disease is restricted by the policy’s step therapy requirements. Prior to approving mesalamine for induction, the member must have had a documented trial of sulfasalazine or balsalazide, and an adequate trial of the preferred formulary generic mesalamine (mesalamine 1.2 g, generic Lialda®) when indicated by the decision pathway.
Induction with the preferred generic mesalamine formulation (mesalamine 1.2 g at 2 tablets per day) is approved for up to 8 weeks with quantity limit. Requests for non‑formulary oral mesalamine for induction require documentation of an adequate prior trial of maximally dosed generic mesalamine (Lialda®).
When treatment does not meet these prior trial requirements or when required documentation is absent, the request for induction in Crohn’s disease should be considered not medically necessary under the policy.
Dosing Thresholds and Coding Notes
Prior Authorization, Step Therapy, and Documentation Requirements
Prior authorization required and governed by stepwise criteria
Prior authorization (PA) is required for 5‑ASA agent requests. Approval decisions follow the policy's stepwise criteria including: a funded diagnosis of ulcerative colitis or ulcerative proctitis; medication prescribed by or in consultation with a gastroenterologist; prior trial of or contraindication to sulfasalazine or balsalazide; and trials of preferred formulary generic mesalamine (mesalamine 1.2 g, generic Lialda) per the decision-tree.
- PA required before coverage decisions are made.
- Decisions follow the numbered decision-path (see criteria steps #1–#9).
Step therapy: require sulfasalazine/balsalazide then preferred mesalamine
Step therapy mandates prior trial of sulfasalazine or balsalazide and an adequate trial of preferred formulary generic mesalamine (mesalamine 1.2 g, generic Lialda) before coverage of non‑formulary oral mesalamine. Olsalazine (Dipentum) maintenance coverage requires intolerance to sulfasalazine plus prior trial of formulary mesalamine and one nonformulary mesalamine agent.
- Non‑formulary oral mesalamine: requires prior trial of sulfasalazine/balsalazide AND adequate trial (>1 month at maximal dose) of mesalamine 1.2 g (Lialda).
- Olsalazine (Dipentum) for maintenance: covered only for patients intolerant of sulfasalazine with prior trial of formulary mesalamine and one nonformulary mesalamine.
Required documentation to support PA and renewals
Documentation must demonstrate a funded diagnosis of ulcerative colitis or ulcerative proctitis, prescriber specialty (or consultation) with a gastroenterologist, evidence of prior trials or contraindications to sulfasalazine or balsalazide, and prior trials of formulary mesalamine; renewals require documentation of treatment efficacy.
- Funded diagnosis of ulcerative colitis or ulcerative proctitis (decision step #1).
- Prescribed by or in consultation with a gastroenterologist (decision step #2).
- Document prior trial of or contraindication to sulfasalazine or balsalazide (decision step #4).
- Document adequate prior trial (>1 month at maximal dose) of formulary mesalamine when required (notes; ⱡ definition).
- For renewals, provide documentation of treatment efficacy (renewal criteria).
Triggers for denial if required trials, specialty, or diagnosis not documented
Requests will be denied if key criteria are not met: if the medication is not prescribed by or in consultation with a gastroenterologist; if prior trial or contraindication to sulfasalazine or balsalazide is not documented for oral mesalamine requests; or if the member does not have a funded diagnosis of ulcerative colitis or ulcerative proctitis.
- Deny PA when prescriber is not a gastroenterologist and no gastroenterology consultation is documented (decision step #2).
- Deny oral mesalamine requests lacking documentation of prior trial/contraindication to sulfasalazine or balsalazide (decision step #4).
- Deny when there is no documentation supporting a funded diagnosis of ulcerative colitis or ulcerative proctitis (decision step #1).
Clinical Background
5‑Aminosalicylic acid (5‑ASA) agents are used to induce and maintain remission in inflammatory bowel disease, most commonly ulcerative colitis and ulcerative proctitis. The policy aligns coverage with guideline‑based step therapy and formulary preferences, prioritizing the preferred generic mesalamine formulation (mesalamine 1.2 g, generic Lialda®) for induction and maintenance.
Approval durations are protocolized: induction approvals for the preferred oral mesalamine are up to 8 weeks, and maintenance approvals are up to 1 year with quantity limits. The policy requires prior trials of sulfasalazine or balsalazide and may require trials of formulary rectal products for distal disease before approving non‑formulary rectal agents.
An adequate trial is defined within the policy context as greater than 1 month of treatment at maximal dose without reduction or remission of symptoms; this definition is used to evaluate requests for non‑formulary agents or step therapy progression.
Key Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.